Blue Matter Blog

Blue Matter Team Gets Ready to Walk the South Coast to Raise Money for Cancer Research
July 25, 2019

The weekend of 31 August – 1 September will be a busy one for Blue Matter team members Zeren Kocak, Linah Richer, Anwen Brown, Nafees Masri, Mariah Peixoto, and Magda Palczynska.  They’ll be putting on their hiking shoes and taking part in this year’s South Coast Challenge to help raise money for cancer research. The …

Oncology Trends: Is Past Performance Predictive of Future Returns? – Part II, Unmet Needs & Future Advancements
July 16, 2019

In Part I of this series, we identified and described four key trends in oncology: Novel Drug Targets and Classes of Therapy Novel Drug Designs Tumor Biology-Based Regimens Diagnostic-Driven, Adaptive Regimens: Precision Medicine Despite the significant advances these trends represent, much unmet need remains in oncology. In this installment, we outline some of those key …

Oncology Trends: Is Past Performance Predictive of Future Returns? – Part I, Trends Overview
July 8, 2019

Over the past 5 years, several ground-breaking advancements in oncology have dramatically advanced the standard of care. These new classes of drugs include the PD(L)1 checkpoint inhibitors, the PARP inhibitors, and the EGFR resistance targeted drugs.  Also included is a general trend towards more precise and targeted treatment decisions, driven by incorporating molecular tests and …

Blue Matter Breakfast Club 2, Nick Leschly, CEO of bluebird bio
Blue Matter Breakfast Club Meeting #2 – A Discussion with Nick Leschly, CEO of bluebird bio
July 1, 2019

The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team.  These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues. The second Breakfast Club meeting was on 17th June 2019 at Skylounge restaurant in Zug, Switzerland.  The …